ITR-251

ITR-251 is a small molecule from Iteria Biopharma. A potent and selective, reversible inhibitor of monoamine oxidase A (MAO-A) with limited capacity to cross the blood-brain barrier. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b NCT07870096 is registered but NOT YET RECRUITING; first in advanced solid tumours, then with androgen receptor pathway inhibitors and ADT in metastatic castration-resistant prostate cancer. If the writer prefers stage to mean dosed patients, use preclinical. Whether it works in people has not been established unless a trial below reports it.